Psychedelics and Health Risks

Psychedelics and Health Risks

Psychedelic risks depend on the substance, your health, medications, surroundings and support. Screening and careful preparation matter, but no one can predict exactly how an experience will unfold. This article covers psychological and physical concerns so you can ask better questions before deciding.

Here is a general outline of what will be reviewed: 

Psychological risks (ref): 

• The Difficult Experience
• Anxiety, panic and depersonalization 
• Reliving Trauma
• Ego dissolution
• Drug-induced psychosis
• Hallucinogen persisting perception disorder
• Comparing Drug Risks: dependence, addiction and harm

Physical: 

• Acute Drug Toxicity / Overdose risk
• Serotonin Syndrome
• Hypertension, cardiovascular disease
• Emergency medical treatment
• Behavioural Risks

Psychological risks: 

The Difficult Experience

• A psychedelic experience can include intense fear, grief, confusion or a sense of losing control. Some distress passes as the drug wears off; difficulties can also continue afterward. A difficult experience is not proof that someone prepared badly or failed to surrender. A survey of people with lasting difficulties describes varied experiences and support needs; it cannot tell us how often these difficulties occur among all users. Research on extended difficulties and support.

Difficult: Reliving Trauma

People with a history of trauma may encounter distressing memories, images or emotions during a psychedelic experience. Some describe more distance or compassion; others become overwhelmed. These experiences do not establish that a memory is accurate or that healing is occurring. Difficulties can persist afterward and deserve appropriate support. Doss et al. (2023); BMJ evidence review (2026).

• If you have a history of trauma, discuss current symptoms and support with an appropriately qualified mental-health professional before considering a psychedelic. Feeling ready to explore something does not guarantee that it will feel manageable during the experience.
• If anxiety, intrusive thoughts, poor sleep or a sense of unreality is affecting daily life, seek help. You do not need to wait a week or reach a particular level of distress. If symptoms are severe, escalating or affecting your ability to stay safe, seek urgent assessment. Read what to do when you do not feel right afterward.

Difficult: Ego Dissolution

Another aspect of a journey that can be difficult is ego dissolution: the usual boundaries of “I” or “self” may feel altered or absent. Some studies associate aspects of this experience with later outcomes, but this does not establish that more is better or necessary. Fear is not a failure to surrender. Grounding and support are valid, and persistent distress deserves attention. BMJ evidence review (2026).

Drug-Induced Psychosis

• A personal or relevant family history of psychosis or bipolar disorder needs particular caution and professional assessment. These histories are commonly excluded from classic psychedelic trials, so reassuring trial findings cannot establish safety for these groups. New loss of contact with reality or symptoms of mania need prompt assessment. Research screening guidance; NIMH’s explanation of bipolar symptoms.

Hallucinogen Persisting Perception Disorder

• Some people report ongoing visual disturbances after psychedelic use. Hallucinogen persisting perception disorder (HPPD) involves recurring or persistent perceptual symptoms that cause distress or interfere with daily life; it is not simply another name for every brief “flashback.” Its frequency is uncertain. Persistent visual changes deserve medical assessment, including consideration of other causes. Systematic review of adverse events.

Comparing Drug Risks

• Comparisons between drugs depend on what is being measured: dependence, physical toxicity, injuries or harm to others. A lower score on a population-level harm chart cannot tell you that a substance is safe for you.

Dependence and addiction involve learning, biology, circumstances and patterns of use. A simple dopamine-versus-serotonin story cannot explain the risk. Classic psychedelics are generally considered to have relatively low dependence potential, but they can still cause harm. MDMA and other substances need separate consideration. BMJ evidence review (2026).

Summary

• Psychological risks extend beyond a difficult few hours. Support can help someone respond to an experience, but personal growth is not guaranteed and should not be expected as the price of distress. Our Integration Guidebook offers reflection prompts; persistent or worsening symptoms need appropriate care.

01

During the experience

Fear, confusion and physical symptoms deserve attention.

02

When things are severe

Collapse, seizures or trouble breathing need emergency help.

03

In the days afterward

Seek assessment for persistent or worsening symptoms. You do not need to wait a week.

Physical risks: 

Acute Drug Toxicity

• Physical risk depends on the substance, the person and other drugs or medicines. Findings from screened and monitored psilocybin or LSD studies cannot establish safety for everyone, or show that an overdose is impossible. NNDC task group, 2025 — clinical consensus statement.
• MDMA with an MAOI can cause life-threatening toxicity; fatal cases with moclobemide have been reported. Do not combine them. This is not evidence that an SSRI with psilocybin carries the same risk. Pilgrim et al., 2012 — fatal MDMA–moclobemide interactions. MDMA can also cause serious toxicity without an MAOI. Other interacting medicines need individual review. Sarparast et al., 2022 — systematic MDMA/psilocybin interaction review.
• MDMA can impair temperature regulation and cause dangerously low blood sodium. Both overheating and excessive water intake can be dangerous. A private setting does not remove those risks, and a fixed drinking schedule is not a safety guarantee. Sarparast et al., 2022 — systematic MDMA/psilocybin interaction review.

Serotonin Syndrome

• Serotonin toxicity is a drug reaction that can range from mild to life-threatening. Confusion or agitation together with overheating, muscle stiffness or repeated involuntary jerking needs urgent assessment. Collapse, seizures or trouble breathing are emergencies. Tell responders what was taken. Read the medication review for details and sources.
• Serotonin-toxicity risk is substance- and combination-specific. The evidence for psilocybin with selected SSRIs differs from the documented danger of MDMA with MAOIs. Small reassuring studies do not prove that every combination is safe. Becker et al., 2022 — psilocybin and escitalopram trial, Pilgrim et al., 2012 — fatal MDMA–moclobemide interactions.
• Do not abruptly stop an SSRI or another psychiatric medication to prepare for a psychedelic experience. Taking an antidepressant does not automatically mean you need to taper. Continuing, changing or tapering a medication is an individual decision with the prescribing clinician, taking into account the particular medication, psychedelic and your current health. Never increase a psychedelic dose to overcome suspected medication-related blunting. Read Medication considerations for the substance-specific evidence and questions to bring to your prescriber.

Medication evidence reviewed: September 27, 2026.

Heart rate, blood pressure and temperature

• Psilocybin, LSD and MDMA can increase heart rate and blood pressure. The significance depends on the substance, your health and other medicines or drugs. Uncontrolled cardiovascular conditions need professional assessment. MDMA also carries important overheating and sodium-balance risks; physical symptoms should not automatically be dismissed as anxiety. Psilocybin adverse-event review; substance-specific interaction review.

Behavioural Risks

• Psychedelics can impair judgement, coordination and the ability to give informed consent. Avoidable hazards include driving, heights, water and situations where someone could take advantage of you. Agree on boundaries beforehand, including touch and privacy. A sitter can provide support but cannot guarantee safety.

Emergency Department Visits

• Surveys and clinical trials measure different kinds of risk in different groups. Emergency-care percentages from self-selected surveys are not a personal risk estimate. Trial participants are screened and monitored, and adverse-event reporting has been inconsistent. Hinkle and colleagues’ systematic review.
• For MDMA, severe overheating, confusion, collapse or seizures require emergency medical care. Do not assume a private setting or a familiar product removes these risks. There is no dose threshold below which this article can promise safety.

Summary

Different substances carry different risks. Screening, medication review, current stability and support all matter. Psychedelics can impair judgment and the ability to give consent. A reassuring study cannot clear an individual to proceed. Read our medication considerations before changing any prescribed treatment.

For the evidence on networks, self-experience and plasticity, see Basic Psychedelic Neuroscience.

Evidence reviewed: September 27, 2026.